Assertio Therapeutics Welcomes Brendan O’Grady as New CEO
Company Announcements

Assertio Therapeutics Welcomes Brendan O’Grady as New CEO

Assertio Therapeutics (ASRT) has provided an announcement.

Assertio Holdings, Inc. has appointed Brendan P. O’Grady as the new CEO, effective May 29, 2024. He brings extensive experience from his previous roles, including CEO of Glenmark Pharmaceuticals’ Global Formulations Business and executive positions at Teva Pharmaceutical Industries. Alongside his CEO role, O’Grady will also join the Board of Directors. His compensation package includes a base salary of $850,000, potential cash bonuses, stock options, and restricted stock units, with provisions for additional benefits under certain termination conditions.

For detailed information about ASRT stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAssertio Therapeutics’ Q3 2024 Earnings Overview
TheFlyAssertio Holdings reports Q3 EPS 3c, consensus (5c)
TheFlyAssertio Therapeutics options imply 29.1% move in share price post-earnings
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App